FIGURE

Fig. 1

ID

ZDB-FIG-230127-17

Publication

Tang Gundersen et al., 2021 - Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulation

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1

CPZ shows dose-dependent cytotoxicity against AML< cell lines and patient cells. (A): AML cell lines (HL-60, OCI-AML3, MOLM-13, and MV4-11) and AML patient cells (P1-4) derived from blood or bone marrow (BM) were incubated in growth conditions for 24 or 48 h with 5, 10, or 20 �M CPZ. Cells were tested for viability as measured by metabolic conversion of the WST-1 reagent, described in detail in the Methods section. CPZ dose?response curves of MOLM-13 cells and cells from blood of patient P1 are shown in (B) and (C) respectively. (D): AML cell lines incubated with 10, 20, or 40 �M CPZ for 24 h were tested for viability using Annexin/PI viability. (E): Flow cytometric dot plots of Annexin/PI viability assay of MOLM-13 cells. Cell were seeded to 2.0 � 10⁵ cells/ml. All experiments were performed in triplicate.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Int J Pharm